GlaxoSmithKline (GSK) and Pfizer are spinning out all HIV/AIDS-related R&D and marketed drugs into a separate, jointly-controlled company.

As life sciences investors shy away from drug development and opt for lower-risk devices and diagnostics, what can Europe learn from Israel’s experience?